X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse ASTRAZENECA PHARMA with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs MYLAN (US) - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ASTRAZENECA PHARMA   MYLAN
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
MYLAN
Dec-14
ASTRAZENECA PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,2784,182-   
Low Rs8832,947-   
Sales per share (Unadj.) Rs228.41,431.7-  
Earnings per share (Unadj.) Rs10.4172.5-  
Cash flow per share (Unadj.) Rs16.3277.6-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs98.8711.7-  
Shares outstanding (eoy) m25.00378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x4.72.5 190.0%   
Avg P/E ratio x104.220.7 504.3%  
P/CF ratio (eoy) x66.412.8 517.4%  
Price / Book Value ratio x10.95.0 218.4%  
Dividend payout %00-   
Avg Mkt Cap Rs m27,0081,348,751 2.0%   
No. of employees `0001.425.0 5.4%   
Total wages/salary Rs m1,5350-   
Avg. sales/employee Rs Th4,210.921,668.5 19.4%   
Avg. wages/employee Rs Th1,132.20-   
Avg. net profit/employee Rs Th191.12,610.3 7.3%   
INCOME DATA
Net Sales Rs m5,710541,712 1.1%  
Other income Rs m123-3,158 -3.9%   
Total revenues Rs m5,833538,555 1.1%   
Gross profit Rs m463134,726 0.3%  
Depreciation Rs m14739,786 0.4%   
Interest Rs m023,367 0.0%   
Profit before tax Rs m43868,416 0.6%   
Minority Interest Rs m0-281 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1792,877 6.2%   
Profit after tax Rs m25965,258 0.4%  
Gross profit margin %8.124.9 32.6%  
Effective tax rate %40.84.2 971.3%   
Net profit margin %4.512.0 37.7%  
BALANCE SHEET DATA
Current assets Rs m3,209476,237 0.7%   
Current liabilities Rs m2,070372,322 0.6%   
Net working cap to sales %20.019.2 104.1%  
Current ratio x1.61.3 121.2%  
Inventory Days Days7278 92.7%  
Debtors Days Days35107 32.6%  
Net fixed assets Rs m790125,324 0.6%   
Share capital Rs m5019,156 0.3%   
"Free" reserves Rs m2,4190-   
Net worth Rs m2,469269,284 0.9%   
Long term debt Rs m0402,285 0.0%   
Total assets Rs m4,6051,084,653 0.4%  
Interest coverage xNM3.9-  
Debt to equity ratio x01.5 0.0%  
Sales to assets ratio x1.20.5 248.3%   
Return on assets %5.68.2 68.9%  
Return on equity %10.524.2 43.3%  
Return on capital %17.713.6 130.2%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-1,7150-   
CASH FLOW
From Operations Rs m8871,209 0.1%  
From Investments Rs m-94-56,157 0.2%  
From Financial Activity Rs mNA-18,763 0.0%  
Net Cashflow Rs m-6-3,712 0.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 70.17 Rs / USD

Compare ASTRAZENECA PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare ASTRAZENECA PHARMA With: STRIDES PHARMA SCIENCE  ABBOTT INDIA  FDC LTD.  ORCHID PHARMA LTD  SUN PHARMA  



Today's Market

US China Trade War Escalations and Election Results: Volatility Set to Rule(Podcast)

India could be the latest direct victim of the US-China trade war. The increasing escalations have already slowed down global growth.

Related Views On News

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

These Dividend Stocks Could Boost Your Returns Better Than You Can Imagine(Profit Hunter)

May 7, 2019

The art of dividend investing is a lot more than investing in companies with high dividend payouts or stocks with high dividend yields...

Limited Upside, Higher Downside(The Honest Truth)

May 6, 2019

The market's irrational reaction may present opportunities for a limited period of time.

3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)

May 10, 2019

The one critical element that has made Amazon a force to reckon with...

A Simple Checklist for Picking Great Dividend Stocks(Profit Hunter)

May 9, 2019

A filtered, neat list of high-dividend stocks with all this dirty work already done for you.

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


May 17, 2019 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - BIOCON COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS